MONTREAL, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial ...
Objective Sarcopenia, defined by reductions in muscle mass and strength, increases the risk of adverse outcomes in patients with rheumatoid arthritis (RA)—driven in part by chronic inflammation—and is ...
Objectives To quantify out-of-pocket (OOP) costs and catastrophic health expenditure (CHE) among patients hospitalised with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results